Logo image of RIGL

RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD

19.57  +0.16 (+0.82%)

After market: 19.57 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to RIGL. RIGL was compared to 566 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. RIGL is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make RIGL a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year RIGL was profitable.
RIGL had a positive operating cash flow in the past year.
RIGL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of 10.66%, RIGL belongs to the best of the industry, outperforming 95.58% of the companies in the same industry.
Looking at the Return On Equity, with a value of 531.78%, RIGL belongs to the top of the industry, outperforming 99.82% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 18.98%, RIGL belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
Industry RankSector Rank
ROA 10.66%
ROE 531.78%
ROIC 18.98%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

RIGL has a better Profit Margin (9.75%) than 93.82% of its industry peers.
Looking at the Operating Margin, with a value of 13.49%, RIGL belongs to the top of the industry, outperforming 94.88% of the companies in the same industry.
RIGL has a Gross Margin of 89.60%. This is amongst the best in the industry. RIGL outperforms 90.64% of its industry peers.
RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.49%
PM (TTM) 9.75%
GM 89.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RIGL has more shares outstanding
Compared to 5 years ago, RIGL has less shares outstanding
RIGL has a better debt/assets ratio than last year.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.47, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
RIGL has a worse Altman-Z score (-8.47) than 70.49% of its industry peers.
RIGL has a debt to FCF ratio of 1.92. This is a very positive value and a sign of high solvency as it would only need 1.92 years to pay back of all of its debts.
RIGL has a Debt to FCF ratio of 1.92. This is amongst the best in the industry. RIGL outperforms 94.52% of its industry peers.
A Debt/Equity ratio of 15.94 is on the high side and indicates that RIGL has dependencies on debt financing.
RIGL has a Debt to Equity ratio of 15.94. This is amonst the worse of the industry: RIGL underperforms 85.16% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 15.94
Debt/FCF 1.92
Altman-Z -8.47
ROIC/WACC1.81
WACC10.5%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.13 indicates that RIGL has no problem at all paying its short term obligations.
The Current ratio of RIGL (2.13) is worse than 74.38% of its industry peers.
A Quick Ratio of 2.04 indicates that RIGL has no problem at all paying its short term obligations.
The Quick ratio of RIGL (2.04) is worse than 73.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 2.04
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.67% over the past year.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 53.38%.
Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)162.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1788.65%
Revenue 1Y (TTM)53.38%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%60.92%

3.2 Future

RIGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.07% yearly.
Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 11.81% on average per year.
EPS Next Y12.77%
EPS Next 2Y37%
EPS Next 3Y55.21%
EPS Next 5Y14.07%
Revenue Next Year14.05%
Revenue Next 2Y14.86%
Revenue Next 3Y14.67%
Revenue Next 5Y11.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.82 indicates a rather expensive valuation of RIGL.
Based on the Price/Earnings ratio, RIGL is valued cheaper than 96.11% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.87, RIGL is valued a bit cheaper.
With a Price/Forward Earnings ratio of 18.46, RIGL is valued on the expensive side.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 94.70% of the companies in the same industry.
RIGL's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.38.
Industry RankSector Rank
PE 20.82
Fwd PE 18.46
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

97.00% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
97.88% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.25
EV/EBITDA 11.68
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

RIGL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 55.21% in the coming years.
PEG (NY)1.63
PEG (5Y)N/A
EPS Next 2Y37%
EPS Next 3Y55.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (4/29/2025, 4:41:34 PM)

After market: 19.57 0 (0%)

19.57

+0.16 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2025-03-04/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners69.99%
Inst Owner Change0.47%
Ins Owners2.63%
Ins Owner Change7.55%
Market Cap349.72M
Analysts76.67
Price Target34.34 (75.47%)
Short Float %10.7%
Short Ratio8.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)572.24%
Min EPS beat(2)67.95%
Max EPS beat(2)1076.54%
EPS beat(4)3
Avg EPS beat(4)288.58%
Min EPS beat(4)-70.03%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)172.77%
EPS beat(12)10
Avg EPS beat(12)127.71%
EPS beat(16)13
Avg EPS beat(16)369.48%
Revenue beat(2)2
Avg Revenue beat(2)19.24%
Min Revenue beat(2)9.15%
Max Revenue beat(2)29.32%
Revenue beat(4)3
Avg Revenue beat(4)9.78%
Min Revenue beat(4)-7.45%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)6.52%
Revenue beat(12)9
Avg Revenue beat(12)12.18%
Revenue beat(16)11
Avg Revenue beat(16)19.34%
PT rev (1m)5.21%
PT rev (3m)7.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-88.82%
EPS NY rev (1m)0%
EPS NY rev (3m)6.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)-1.46%
Revenue NY rev (3m)-0.54%
Valuation
Industry RankSector Rank
PE 20.82
Fwd PE 18.46
P/S 1.95
P/FCF 11.25
P/OCF 11.11
P/B 106.36
P/tB N/A
EV/EBITDA 11.68
EPS(TTM)0.94
EY4.8%
EPS(NY)1.06
Fwd EY5.42%
FCF(TTM)1.74
FCFY8.89%
OCF(TTM)1.76
OCFY9%
SpS10.03
BVpS0.18
TBVpS-1.33
PEG (NY)1.63
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.66%
ROE 531.78%
ROCE 24.03%
ROIC 18.98%
ROICexc 81.83%
ROICexgc N/A
OM 13.49%
PM (TTM) 9.75%
GM 89.6%
FCFM 17.33%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.09
Health
Industry RankSector Rank
Debt/Equity 15.94
Debt/FCF 1.92
Debt/EBITDA 1.98
Cap/Depr 17.77%
Cap/Sales 0.22%
Interest Coverage 3.44
Cash Conversion 119.12%
Profit Quality 177.72%
Current Ratio 2.13
Quick Ratio 2.04
Altman-Z -8.47
F-Score7
WACC10.5%
ROIC/WACC1.81
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1788.65%
EPS Next Y12.77%
EPS Next 2Y37%
EPS Next 3Y55.21%
EPS Next 5Y14.07%
Revenue 1Y (TTM)53.38%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%60.92%
Revenue Next Year14.05%
Revenue Next 2Y14.86%
Revenue Next 3Y14.67%
Revenue Next 5Y11.81%
EBIT growth 1Y217.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.99%
EBIT Next 3Y76.86%
EBIT Next 5YN/A
FCF growth 1Y249.81%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y647.99%
OCF growth 3Y74.92%
OCF growth 5YN/A